Author(s):
Jyotiram A. Sawale, Sandip R. Fulzele, Suhas P. Padmane
Email(s):
jyotisawale@gmail.com , sandipfulzele79@gmail.com , suhaspadmane@gmail.com
DOI:
10.52711/0974-360X.2024.00494 
Address:
Jyotiram A. Sawale1, Sandip R. Fulzele2, Suhas P. Padmane3
1Krishna Institute of Pharmacy, Krishna Vishwa Vidyapeeth Deemed to be University, Formerly Krishna Institute of Medical Sciences (Deemed to be University) Karad, Maharashtra, India.
2Shri Rawatpura Sarkar College of Pharmacy, Shri Rawatpura Sarkar University, Raipur, CG India.
3Gurunanak College of Pharmacy, Mauza-Nari, Near Dixit Nagar, Kamptee Road, Nagpur - 440026, Maharashtra State, India.
*Corresponding Author
Published In:
Volume - 17,
Issue - 7,
Year - 2024
ABSTRACT:
Disulfiram has been the first choice of drug for the physician to treat alcoholism. The oral effect of disulfiram is limited because of less patient compliance and poor bioavailability. Attempts were made to develop subcutaneously implantable disulfiram pellet or tablet dosage forms to reduce oral medication failure. The present study attempts to prepare and evaluate an implant of disulfiram by using a direct compression method. The effect of agitation speed with three different in vitro dissolution methods i.e., Vial Method (VM) (5min Shaking at sampling time), Rotary Flask Shaker Method (RFM) (25 RPM), and Intrinsic Dissolution Method (IDM) (50 RPM) were studied for in-vitro release of disulfiram implant. The results showed the steady release rate of formulation (S3, S7, S11, and S15) at varying compression forces obtained by three methods (VM, RFM and IDM) are different significantly with p value <0.0001. Thus, the effect of agitation speed with three different methods (VM, RFM and IDM) had a distinct effect of plain disulfiram Implant on in-vitro release. All the formulations were subjected to different dissolution kinetic treatment models (Zero order, First order, Higuchi Square root, and Korsmeyer Peppas), upon studying the release and release kinetics, the release kinetic mechanism was found to be zero order from all formulations.
Cite this article:
Jyotiram A. Sawale, Sandip R. Fulzele, Suhas P. Padmane. Effect of Agitation Speed: Three Different Dissolution Methods on in-vitro Release of Plain Disulfiram Implant. Research Journal of Pharmacy and Technology. 2024; 17(7):3163-8. doi: 10.52711/0974-360X.2024.00494
Cite(Electronic):
Jyotiram A. Sawale, Sandip R. Fulzele, Suhas P. Padmane. Effect of Agitation Speed: Three Different Dissolution Methods on in-vitro Release of Plain Disulfiram Implant. Research Journal of Pharmacy and Technology. 2024; 17(7):3163-8. doi: 10.52711/0974-360X.2024.00494 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2024-17-7-27
6. REFERENCES:
1. Pradnya MM, Manish MR, Dipti GP. Controlled Drug Delivery System-A Novel Approach. Asian J. of Pharm. Tech. 2018; 8(3): 161-164. doi: 10.5958/2231-5713.2018.00026.0.
2. Jaganath S, Asha D, Sathesh KS, Keerthi SN, Senthil KK. Oral Controlled Drug Delivery System – A Review. Research J. Pharm. and Tech. 2018; 11(2): 797-8004. doi: 10.5958/0974-360X.2018.00151.8.
3. Gawai MN, Surwade KS, Phadatare DG. Emphasis on Controlled Drug Delivery System- A Review. Research J. Pharm. Dosage Forms and Technology. 2018; 10(4): 215-219. doi: 10.5958/0975-4377.2018.00033.2.
4. Vinod M, et al. A Brief Review on Controlled Drug Delivery System. RJPDFT. 2021; 13(1): 41-53. doi: 10.5958/0975-4377.2021.00008.2.
5. Sowjanya M, Subhashis D, Lavanya P, Thejovathi R, Niranjan BM. Polymers used in the Designing of Controlled Drug Delivery System. Research J. Pharm. and Tech. 2017; 10(3): 903-912. doi: 10.5958/0974-360X.2017.00168.8.
6. Debjit B, Rishab B, Sampath KP. Extended-Release Drug Delivery-An Effective Way of Novel Drug Delivery System. RJPDFT. 2018; 10(4): 233-244. doi: 10.5958/0975-4377.2018.00035.6.
7. Sunil K, Anil K, Vaibhav G, Kuldeep M, Pankaj R. Oral Extended-Release Drug Delivery System: A Promising Approach. Asian J. Res. Pharm. Sci. 2012; 2(3): 101-106.
8. Preeti K, Suresh GB, Abhishek KS, Sanjay JD. Ocular implants as drug delivery device in ophthalmic therapeutics: An overview. Research J. Pharm. and Tech. 2014; 7(6): 665-676.
9. Martindale The extra Pharmacopoeia. 31st ed. Royal Pharmaceutical Society, London.1996.
10. https://www.rxlist.com/antabuse-drug.htm
11. Boess C, Bogl KW. Influence of Radiation Treatment on Pharmaceuticals-A Review: Alkaloids, Morphine Derivatives, and Antibiotics. Drug dev. Ind. Pharm. 1996; 22: 495-529. doi:10.3109/03639049609108354
12. The Indian Pharmacopoeia Vol 1. 4th ed. Controller of Publication, Delhi. 1996.
13. British Pharmacopoeia Vol 1. 15th ed. H. M. Stationary office, London. 1993.
14. Hoffman AS, Afrassiabi A, Dong LC. Thermally reversible hydrogels: II. Delivery and selective removal of substances from aqueous solutions. J. Cont. Rel. 1986; 4: 213. https://doi.org/10.1016/0168-3659 (86)90005-2.
15. Tapan KG, Ravikant S, Kulesh K, Amit A, Ajazuddin HB, Dulal KT. In-vitro quality control measurement of some commercially available sustained release tablet containing diclofenac sodium. Research J. Pharm. and Tech. 2012; 5(5): 687-690.
16. The United States Pharmacopoeia, XXII, The United States Pharmacopoeial Convention, Rockville, MD. 1990.
17. Mandal TK.In vitro dissolution method for evaluation of buprenorphine in situ gel formulation: A technical note. Drug dev. Ind. Pharm.1999; 25: 773-779. doi:10.1208/pt0803062.
18. Dankwarts MP, Fassihi A. Implantable controlled release Drug Delivery System: A Review. Drug dev. Ind. Pharm. 1991; 17(11): 1465-1502. https://doi.org/10.3109/03639049109026629.
19. Chien YW, Lin S. Optimization of treatment by applying programmable rate-controlled drug delivery technology. Clin. Pharmacokinet. 2002; 41(15): 1267–1299. doi:10.2165/00003088-200241150-00003.
20. Schliecker G and Schmidt. Hydrolytic degradation of poly(lactide-co-glycolide) films: effect of oligomers on degradation rate and crystallinity. Int. J. Pharm. 2003; 6; 266(1-2): 39-49. doi: 10.1016/s0378-5173(03)00379-x.
21. Girish PK, Sreenivasa MR. Formulation and Evaluation of Extended Release Ocular Inserts prepared from Synthetic and Natural Biodegradable - Biocompatible Polymers. Research J. Pharm. and Tech. 2014; 7(1): 48-51.
22. The United States Pharmacopoeia, XXVI, The United States Pharmacopoeial Convention, Rockville, MD. 1990.
23. Gratzil MM, Robert A, Pitt CG, Zweidinger JR. Schindler. Aliphatic polyesters II. The degradation of poly (DL-lactide), poly (epsilon-caprolactone), and their copolymers in vivo. Biomaterials. 1981; 2(4): 215-20. doi:10.1016/0142-9612(81)90060-0.
24. Yamakawa C, Kawahara M, Watanabe S, Miyake Y. Sustained Release of Insulin by Double-Layered Implant Using Poly(D,L-Lactic Acid). J. Pharm. Sci. 1990; 79: 505-509. doi: 10.1002/jps.2600790610.
25. Ramchandani M and Robinson D. In vitro and in vivo release of ciprofloxacin from PLGA 50:50 implants. J. Cont. Rel. 1998; 54: 167-175. doi: 10.1016/s0168-3659(97)00113-2.
26. Gerrin JR, Rosenberg CM, Manohar V. Disulfiram maintenance in out-patient treatment of alcoholism. Arch. Gen. Psychiatry. 1973; 28: 798. doi: 10.1001/archpsyc.1973.01750360034004.